INCY - INCYTE CORP

95.47
-1.270   -1.330%

Share volume: 905,061
Last Updated: 04-23-2026
Business Services/Services – Research, Development, Testing Labs: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$96.74
-1.27
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 0%
Dept financing 42%
Liquidity 75%
Performance 52%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.50%
1 Month
5.35%
3 Months
-6.93%
6 Months
4.59%
1 Year
61.90%
2 Year
84.52%
Key data
Stock price
$95.47
P/E Ratio 
15.07
DAY RANGE
$95.10 - $97.25
EPS 
$6.59
52 WEEK RANGE
$57.77 - $112.29
52 WEEK CHANGE
$61.38
MARKET CAP 
19.391 B
YIELD 
N/A
SHARES OUTSTANDING 
199.014 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-29-2025
BETA 
0.75
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,288,878
AVERAGE 30 VOLUME 
$1,288,601
Company detail
CEO: Herve Hoppenot
Region: US
Website: incyte.com
Employees: 2,320
IPO year: 1993
Issue type: Common Stock
Market: XNAS
Industry: Business Services/Services – Research, Development, Testing Labs
Sector: Services

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD) It also develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Recent news